Saved Results

No results saved yet.

Enter a patient name and hit Save on a result.

Clinical calculator summary

PI-RADS™ v2.1 (Prostate MRI)

PI-RADS™ v2.1 is the standard reporting system for multiparametric MRI of the prostate.

Evidence-based context for fast calculator use

Purpose:
PI-RADS v2.1 stratifies prostate MRI lesions by likelihood of clinically significant cancer to guide biopsy decision-making in urology.
Population:
patients undergoing prostate cancer diagnostic, pathologic, recurrence, or molecular-risk assessment
Factors:
PI-RADS Assessment Category
Reference:
Turkbey B, Rosenkrantz AB, Haider MA, et al. Prostate Imaging Reporting and Data System Version 2.1: 2019 Update of Prostate Imaging Reporting and Data System Version 2. Eur Urol. 2019;76(3):340-351.
HomePI-RADS™ v2.1 (Prostate MRI)
Pin your most used calculators here by clicking the star in the dropdown.

PI-RADS™ v2.1 (Prostate MRI)

Clinical Context & Background

PI-RADS™ v2.1 is the standard reporting system for multiparametric MRI of the prostate. It assigns a score (1-5) representing the likelihood that a lesion represents clinically significant cancer (Gleason ≥ 7).
Primary Source EvidenceTurkbey B, Rosenkrantz AB, Haider MA, et al. Prostate Imaging Reporting and Data System Version 2.1: 2019 Update of Prostate Imaging Reporting and Data System Version 2. Eur Urol. 2019;76(3):340-351.
Formula Logic
Categorical assessment based on DWI, ADC, and T2W features.

Reference Data

PI-RADS ScoreLikelihood of Significant Cancer
1Very Low
2Low
3Intermediate (Equivocal)
4High
5Very High

Clinical Workflow

Use, Interpret, And Continue The Patient Pathway

Expand for workflow guidance, limitations, examples, and related next steps.

When To Use

  • Use PI-RADS™ v2.1 (Prostate MRI) when pI-RADS v2.1 stratifies prostate MRI lesions by likelihood of clinically significant cancer to guide biopsy decision-making in urology.
  • Confirm that the patient, diagnosis, disease phase, and available inputs match the cited model before calculation.

How To Interpret

  • Interpret the displayed result using the calculator-specific formula and reference table, spanning 1 through 5.
  • A boundary result should prompt input verification and clinical review rather than false precision.

What To Do Next

  • Confirm biopsy versus prostatectomy setting, PSA timing, grade group, clinical/pathologic stage, imaging, life expectancy, and treatment history.
  • Document the inputs, result, timing, and clinical context so the assessment can be reproduced.

Limitations

  • Diagnostic, post-prostatectomy, genomic, and recurrence tools must be used only at their intended decision point.
  • The result supports clinician judgment and does not independently determine treatment.

Validated Population

patients undergoing prostate cancer diagnostic, pathologic, recurrence, or molecular-risk assessment

How to apply this result

For a representative case, verify PI-RADS Assessment Category, calculate the result, and confirm that its classification matches the highlighted reference band before continuing the disease-specific pathway.

Prostate Cancer hubContinue to related calculators and clinical workflow resources.

Share This Calculator

Share:

Related Tools

D'Amico Risk ClassificationEpstein Criteria (Insignificant Cancer)Gleason Score & ISUP Grade

Frequently Asked Questions

When should PI-RADS™ v2.1 (Prostate MRI) be used?

Use it for patients undergoing prostate cancer diagnostic, pathologic, recurrence, or molecular-risk assessment when all required inputs and the intended clinical setting are confirmed.

Can PI-RADS™ v2.1 (Prostate MRI) determine treatment by itself?

No. Interpret the result with the cited evidence, complete clinical assessment, current guidelines, and patient-specific goals.

Evidence-based oncology decision support. Verify with clinical guidelines.